Greenwich LifeSciences Provides Update on Corporate Events
November 18, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
November 14, 2024 09:00 ET
|
ABVC BioPharma, Inc.
ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could...
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
November 13, 2024 17:15 ET
|
Biofrontera Inc.
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total...
Nordicus Partners Corporation Acquires Bio-Convert ApS
November 11, 2024 14:50 ET
|
Nordicus Partners Corporation
Beverly Hills, California., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
October 31, 2024 10:32 ET
|
Biofrontera Inc.
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is...
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
October 15, 2024 08:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
October 08, 2024 08:00 ET
|
Palisade Bio, Inc.
– Live webcast fireside chat on Tuesday, October 15th at 4:30 PM ET Carlsbad, CA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...
COSCIENS Biopharma Announces Change to Board of Directors
October 08, 2024 07:30 ET
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
September 25, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted...
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
September 25, 2024 08:00 ET
|
Palisade Bio, Inc.
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose – Completion of pre- Clinical Trial Application (CTA)...